🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "significant breakthrough" in the battle against drug-resistant strains of the pathogen, according to researchers.

A Global Public Health Issue

Cases of gonorrhoea are on the rise around the world, with figures suggesting over 82 million infections annually. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Within England, cases have reached a all-time high, while rates across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an critical and opportune step in the context of growing infection rates, increasing antimicrobial resistance and the extremely scarce therapeutic options at this time.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The WHO has designated it as a "priority pathogen". A tracking program showed that the effectiveness of primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

A Pair of Novel Treatment Options Gain Authorization

Zoliflodacin, marketed under the name a brand name, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to serious health problems, including the inability to conceive. Experts anticipate that focused deployment of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, created by the drugmaker GSK, was also approved in the same week. This drug, which is additionally indicated for UTIs, was demonstrated in studies to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Partnership

This new treatment was the result of a new, not-for-profit approach for drug creation. The charitable organization Global Antibiotic Research & Development Partnership partnered with the drug firm its industry partner to see it through.

“This authorization signifies a huge turning point in the treatment of highly resistant gonorrhoea, which until now has been outpacing antibiotic development.”

Clinical Trial Data and Global Access

As per findings released by a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This puts it on an comparable level with the current standard treatment, which involves two antibiotics. The research enrolled nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, the non-profit has the authority to make available and distribute the drug in numerous regions with limited resources.

Medical professionals treating patients have shared positive views. Access to a single-dose, oral treatment of this kind is seen as a "game-changer" for public health efforts. This is considered crucial to reduce the burden of the infection for patients and to stop the proliferation of highly drug-resistant gonorrhoea globally.